Agilent Technologies to Acquire Digital Pathology Firm Proscia

The all-cash acquisition, valued at up to $270 million, aims to integrate advanced software into diagnostic workflows.

Updated on Oct. 26, 2026 in Healthcare

Isometric editorial illustration of a glass tissue slide on a laboratory bench, symbolizing the integration of digital diagnostic pathology software. — Agilent Technologies has reached an agreement to acquire digital pathology firm Proscia in an all-cash deal valued at up to $270 million. AI Illustration. Upload story photo >

Live Poll

Do you believe large corporate acquisitions of specialized software firms generally improve service outcomes for users?

Agilent Technologies has reached an agreement to acquire the digital pathology company Proscia in an all-cash deal worth up to $270 million. Proscia will be folded into Agilent's Life Sciences and Diagnostics Markets Group once the transaction is finalized.

Why it matters

This move allows Agilent to bridge its existing diagnostic instruments and reagents with Proscia's software, creating a more cohesive ecosystem for tissue analysis. The integration aims to streamline complex diagnostic workflows for thousands of healthcare and pharmaceutical partners.

Proscia generated over $18 million in revenue over the last year while serving more than 4,000 laboratories and clinics. The firm counts 16 of the world's 20 largest pharmaceutical companies among its existing customers.

The players

Agilent Technologies

This is a global leader in life sciences, diagnostics, and applied chemical markets providing instruments and software for laboratories.

Proscia

This company is a provider of digital pathology solutions, headquartered in Philadelphia, PA, that uses software to advance cancer research and diagnostics.

The details

Proscia, which maintains a digital pathology platform with FDA 510(k) clearance, was recognized as a 2026 Best in KLAS winner. The acquisition is designed to enhance Agilent's capabilities in the growing pathology sector.

September 2022: The companies entered a multiyear distribution agreement.
2026: Proscia was named a Best in KLAS winner for digital pathology.
Early fiscal 2027: The acquisition is expected to reach its closing date.

Market Landscape

This acquisition reflects a broader consolidation trend within the diagnostic technology sector as legacy hardware firms aggressively acquire software-driven platforms. It positions Agilent to compete more effectively against rivals by controlling the end-to-end data pipeline for tissue analysis.

Healthcare providers currently using Proscia's platform may see service integration benefits as the company transitions into the Agilent portfolio. Customers should monitor for updates regarding software compatibility and any potential changes to support services post-acquisition.

The takeaway

This acquisition highlights the increasing necessity for diagnostic firms to pair physical hardware with advanced digital software platforms. Healthcare organizations should expect a more unified approach to digital pathology as these two entities integrate their respective diagnostic tools.